A retrospective study demonstrated that NSCLC patients with EGFR mutations have a better outcome with gefitinib treatment than patients with the wild-type EGFR gene (Mitsudomi et al, 2005). This evidence concerns the gene EGFR and non-small cell lung carcinoma.